286 results on '"Janssen, Jeroen J. W. M."'
Search Results
2. Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia
3. Mucositis-associated bloodstream infections in adult haematology patients with fever during neutropenia: risk factors and the impact of mucositis severity
4. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
5. Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures
6. Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment
7. Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial
8. Conditional relative survival among adult patients with chronic myeloid leukemia in the tyrosine kinase inhibitor era: a population-based study in the Netherlands
9. Two decades of targeted therapies in acute myeloid leukemia
10. Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989–2017
11. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes
12. Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia
13. BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population
14. Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile
15. Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
16. Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial
17. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes.
18. S155: PROGNOSTIC FACTORS FOR 3-YEAR MAJOR MOLECULAR RESPONSE MAINTENANCE IN CHRONIC MYELOID LEUKAEMIA PATIENTS IN THE EUROPEAN STOP KINASE INHIBITORS (EURO-SKI) TRIAL
19. S159: HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO-SKI STUDY
20. Feasibility of and patients’ perspective on nilotinib dried blood spot self-sampling
21. Validation of the EUTOS long-term survival score in a recent independent cohort of “real world” CML patients
22. Clinical Impact of Polymerase Chain Reaction–based Aspergillus and Azole Resistance Detection in Invasive Aspergillosis: A Prospective Multicenter Study
23. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
24. Clinical impact of PCR-based Aspergillus and azole resistance detection in invasive aspergillosis. A prospective multicenter study
25. Correction: Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989–2017
26. A Systematic Review of the Evidence of Hematopoietic Stem Cell Differentiation to Fibroblasts
27. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis
28. Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis
29. Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
30. A retrospective observational research study to describe the real‐world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands
31. The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018
32. Asciminib monotherapy in patients with CML-CP without BCR::ABL1T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
33. DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia
34. The wider perspective: twenty years of clinical trials in myelodysplastic syndromes
35. Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification
36. Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML
37. Bimodal expression of potential drug target CLL‐1 (CLEC12A) on CD34+ blasts of AML patients
38. TRough versus AUC Monitoring of cyclosporine: A randomized comparison of adverse drug reactions in adult allogeneic stem cell recipients (TRAM study)
39. Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors
40. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group
41. Correction:Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989–2017 (Leukemia, (2020), 34, 12, (3408-3412), 10.1038/s41375-020-0902-1)
42. Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells
43. Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands
44. The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018.
45. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
46. MRD Tailored Therapy in AML: What We Have Learned So Far
47. IGFBP7 activates retinoid acid–induced responses in acute myeloid leukemia stem and progenitor cells
48. Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient views
49. Mobilized peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT
50. The wider perspective: twenty years of clinical trials in myelodysplastic syndromes.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.